Iron removal by desferrioxamine during haemodialysis: in vitro studies.
To find the best way of using desferrioxamine (DFO) in iron (Fe) overloaded patients on regular haemodialysis (HD) treatment, we investigated Fe removal in a standard in vitro haemodialysis model by measuring 59Fe activity in plasma and dialysate after the addition of DFO as a constant infusion during or as a bolus at different time intervals before haemodialysis. Data were compared with those obtained without DFO at normal or high plasma Fe concentrations and by haemofiltration (HF). In summary HF was superior to haemodialysis for Fe removal. No DFO was needed to dialyse high plasma Fe concentrations whereas the efficiency of removal of normal plasma Fe content increased with equilibration time of DFO before haemodialysis. For treatment of Fe overload DFO is therefore recommended to be given after each haemodialysis treatment.
D002648:Child; D003676:Deferoxamine / Q000627:therapeutic use*; D006801:Humans; D066298:In Vitro Techniques; D007501:Iron / Q000097:blood* / Q000302:isolation & purification; D006435:Renal Dialysis / Q000379:methods*
D007501:Iron; D003676:Deferoxamine